PT -期刊文章AU -詹金斯,克里斯汀·r . AU -温Fu-Qiang AU -马丁、埃里森AU -巴恩斯,Peter j . AU -切利,Bartolome盟——钟,南山AU -郑,《金瓶梅盟——Scaria西班牙AU -迪坦拿Gian-Luca AU -布拉德伯里,托马斯•AU - Berend Norbert ED -TI -低剂量糖皮质激素和茶碱对COPD急性加重风险的影响:tasc随机对照试验援助- 10.1183/13993003.03338 -2020 DP - 2021年6月01 TA -欧洲呼吸杂志》第六PG - 2003338 - 57 IP - 6 4099 - //www.qdcxjkg.com/content/57/6/2003338.short 4100 - //www.qdcxjkg.com/content/57/6/2003338.full所以欧元和J2021 6月01;57 AB -背景慢性阻塞性肺病(COPD)的最高负担发生在低收入和中等收入国家。低成本的口服药物如果有效，可以使负担得起的、可获得的慢性阻塞性肺病治疗成为可能。在中国37个中心进行的一项随机、三臂、双盲、双假、安慰剂对照研究中，有症状的中度至极重度COPD患者按1:1:1随机分组，安慰剂每日2次，安慰剂每日1次。小剂量茶碱100mg每日2次加安慰剂每日1次或小剂量茶碱100mg每日2次加低剂量口服强的松5mg每日1次，连续48周。主要终点是年化恶化率。结果随机抽取1670名受试者，1242人完成了研究(1142人在48周时获得了可接受的数据)。受试者(75.7%男性)平均年龄64.4岁，平均±sd基线1 s后用力呼气容积(FEV1) 1.1±0.4 L(预测42.2%)，圣乔治呼吸问卷(SGRQ)评分45.8±20.1。 There were negligible differences between annualised exacerbation rates across the three treatments: 0.89 (95% CI 0.78–1.02) on theophylline plus prednisone, 0.86 (95% CI 0.75–0.99) on theophylline plus placebo and 1.00 (95% CI 0.87–1.14) on placebo. The rate ratio for theophylline plus prednisone versus pooled theophylline plus placebo and placebo was 0.96 (95% CI 0.83–1.12), for theophylline plus placebo versus placebo was 0.87 (95% CI 0.73–1.03; p=0.101) and for theophylline plus prednisone versus placebo was 0.90 (95% CI 0.76–1.06; p=0.201). Secondary outcomes of hospitalisations, FEV1, SGRQ and COPD Assessment Test score showed no statistically significant difference between treatment arms. Serious adverse events other than exacerbations were <2% and did not differ between treatment arms.Conclusions Low-dose theophylline alone or in combination with prednisone did not reduce exacerbation rates or clinically important secondary end-points compared with placebo.This large, rigorously conducted RCT showed that the combination of low-dose theophylline and prednisone did not affect exacerbation rate in patients with moderate to severe COPD in China https://bit.ly/2KSQ2BK